Feitianvision Holdings (PTHL.US) plans to list on NASDAQ. The China Securities Regulatory Commission has requested clarification on the listing issuance method and other related information.

On October 13th, the International Department of the China Securities Regulatory Commission (CSRC) announced the supplementary materials requirements for overseas issuance and listing (September 22nd, 2023 - September 28th, 2023). Among them, Feitian Zhaoye (PTHL.US) was issued supplementary material requirements, requesting the company to explain the specific plan for this IPO, including the issuance method and scale. On October 11th, Feitian Zhaoye officially submitted an IPO application to the U.S. Securities and Exchange Commission (SEC), intending to use PTHL as the stock code and apply for listing on NASDAQ. The announcement states that the CSRC has requested Feitian Zhaoye to supplement the following matters and request lawyers to verify and provide clear legal opinions: 1. Please explain the specific plan for this IPO, including the issuance method and scale. 2. Please explain the reasons and compliance of Beijing Feitian Zhaoye Technology Co., Ltd., the main domestic operating entity, for not fully paying the registered capital, and whether it has a significant impact on the company's business operations and debt repayment ability. 3. Regarding the equity structure: (1) Conclusive opinions on the compliance of offshore architecture construction and return investment involving foreign exchange registration, overseas investment, and foreign investment regulatory procedures. (2) Please explain the basis and fairness of the price for the acquisition of Beijing Feitian Zhaoye Technology Co., Ltd. by Beijing Jingrui Xi Medical Technology Co., Ltd., and the compliance of tax treatment, whether it is in line with the "Regulations on the Acquisition of Domestic Enterprises by Foreign Investors". According to the information, Feitian Zhaoye was established in 1998, headquartered in Beijing, and is a medical solution provider dedicated to the development and commercialization of near-distance treatment planning software specifically for radioactive seed implantation. Seed implantation therapy is a form of radiation therapy for cancer patients, which kills cancer cells and reduces tumor size by placing radioactive sources inside the patient's body. In terms of finance, Feitian Zhaoye's revenue for the fiscal year 2021-2022 was $700,000 and $680,000, respectively, with corresponding net profits of $190,000 and $84,000.